- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03417284
Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation
Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule(s) and Dose(s) of Melphalan for Injection (Evomela) as a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the optimal dose and schedule of melphalan for injection (melphalan hydrochloride [Evomela]) prior to autologous hematopoietic stem cell transplantation (auto-HCT) for multiple myeloma (MM).
II. To collect the pharmacokinetic data and compare the exposure-response evaluations between the 2 infusion schedules.
SECONDARY OBJECTIVES:
I. To determine the incidence of treatment related mortality (TRM) at day 90 after auto-HCT in newly diagnosed myeloma patients treated on different schedules and doses of Evomela.
II. To determine the rate of minimal residual disease (MRD) negative complete response (CR) rate at day 90 after auto-HCT in newly diagnosed myeloma patients treated on different schedules and doses of Evomela.
III. To determine the progression-free survival (PFS) after auto-HCT in newly diagnosed myeloma patients treated on different schedules and doses of Evomela.
OUTLINE: This is a phase I, dose escalation study of melphalan hydrochloride followed by a phase II study.
PREPARATIVE REGIMEN: Participants are randomized to 1 of 2 groups.
GROUP 1: Participants receive melphalan hydrochloride intravenously (IV) over 30-60 minutes on day -2.
GROUP 2: Participants receive melphalan hydrochloride IV over 8-9 hours on day -2.
TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes.
POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz subcutaneously (SC) once daily (QD) starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an absolute neutrophil count (ANC) of 0.5 x 10^9/L.
After completion of study treatment, participants are followed up at 3 months, every 3 months for 1 year, and then annually for 1 year.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with non-relapsed multiple myeloma in complete response (CR), partial remission (PR), very good partial remission (VGPR), or symptomatic stable disease (no evidence of progression) including patients with light chain multiple myeloma (MM) detected in the serum by free light chain assay OR
- Patients with non-secretory multiple myeloma (absence of a monoclonal protein [M protein] in serum as measured by electrophoresis [serum protein electrophoresis (SPEP)] and immunofixation (serum immunofixation electrophoresis [SIFE]) and the absence of Bence Jones protein in the urine [urine protein electrophoresis (UPEP)] defined by use of conventional electrophoresis and immunofixation [urine immunofixation electrophoresis (UIFE) techniques]) but with measurable disease on imaging studies like magnetic resonance imaging (MRI), computed tomography (CT) scan or positron emission tomography (PET) scan.
- Patients who have received at least two cycles of initial systemic therapy and are within 2 to 12 months of the first dose. Mobilization therapy is not considered initial therapy.
- Karnofsky performance score 70% or higher.
- Left ventricular ejection fraction at rest > 40% within 3 months of registration.
- Bilirubin < 2 x the upper limit of normal (except patients with Gilbert syndrome in whom bilirubin level of > 2 x upper normal limit will be allowed)
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x the upper limit of normal.
- Creatinine clearance of >= 40 mL/min, estimated or calculated using the Cockcroft-Gault equation.
- Pulmonary function: diffusing capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1), forced vital capacity (FVC) > 50% of predicted value (corrected for hemoglobin) within 3 months of registration.
- All female and male subjects of reproductive potential must consent to the use of effective contraceptive methods as advised by the study doctor during treatment.
- Signed informed consent form.
Exclusion Criteria:
- Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and progression of clinical symptoms).
- Patients seropositive for the human immunodeficiency virus (HIV).
- Patients with history of myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
- Patients participating in an investigational new drug protocol within 14 days before enrollment.
- Female patients who are pregnant (positive beta-human chorionic gonadotropin [b-HCG]) or breast feeding.
- Prior hematopoietic cell transplantation allogeneic or autologous (A prior autologous HCT will be allowed as long as it was part of tandem transplantation).
- Prior organ transplant requiring immunosuppressive therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1 (melphalan hydrochloride, HSCT, filgrastim)
PREPARATIVE REGIMEN: Participants receive melphalan hydrochloride IV over 30-60 minutes on day -2. TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes. POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10^9/L. |
Given SC
Other Names:
Given IV
Other Names:
Undergo HSCT
Other Names:
|
Experimental: Group 2 (melphalan hydrochloride, HSCT, filgrastim)
PREPARATIVE REGIMEN: Participants receive melphalan hydrochloride IV over 8-9 hours on day -2. TRANSPLANT: Participants in both groups undergo donor stem cell transplantation IV on day 0 over 30-60 minutes. POST-TRANSPLANT: Participants in both groups receive filgrastim-sndz SC QD starting on day 5 and continuing in the absence of disease progression, unacceptable toxicity, or until evidence of an ANC of 0.5 x 10^9/L. |
Given SC
Other Names:
Given IV
Other Names:
Undergo HSCT
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of toxicity of melphalan hydrochloride
Time Frame: Within 30 days after the start of infusion
|
Toxicity will be defined as grade 4 mucositis or any grade 4 or 5 non-hematologic or non-infectious toxicity occurring within 30 days from the start of infusion.
|
Within 30 days after the start of infusion
|
The Pharmacokinetics of melphalan hydrochloride parameters will assessed.
Time Frame: Up to 1 year
|
The investigators will determine pharmacokinetic parameters such as Cmax for each patient using the melphalan plasma concentrations at various time points described above.The investigators will also examine the correlation of theses PK parameters such as (AUC, Clearance, Cmax) with efficacy outcomes (such as OS, PFS) and toxicities (such as mucositis).
|
Up to 1 year
|
The Pharmacokinetics of melphalan hydrochloride parameters will assessed.
Time Frame: Up to 1 year
|
The investigators will determine pharmacokinetic parameters such as, Clearance for each patient using the melphalan plasma concentrations at various time points described above.The investigators will also examine the correlation of theses PK parameters such as (AUC, Clearance, Cmax) with efficacy outcomes (such as OS, PFS) and toxicities (such as mucositis).
|
Up to 1 year
|
The Pharmacokinetics of melphalan hydrochloride parameters will assessed.
Time Frame: Up to 1 year
|
The investigators will determine pharmacokinetic parameters such as Half-life for each patient using the melphalan plasma concentrations at various time points described above.The investigators will also examine the correlation of theses PK parameters such as (AUC, Clearance, Cmax) with efficacy outcomes (such as OS, PFS) and toxicities (such as mucositis).
|
Up to 1 year
|
The Pharmacokinetics of melphalan hydrochloride parameters will assessed.
Time Frame: Up to 1 year
|
The investigators will determine pharmacokinetic parameters such as AUC (area under the curve) for each patient using the melphalan plasma concentrations at various time points described above.The investigators will also examine the correlation of theses PK parameters such as (AUC, Clearance, Cmax) with efficacy outcomes (such as OS, PFS) and toxicities (such as mucositis).
|
Up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: From the date of Evomela injection up to 1 year
|
PFS will be computed from the date of Evomela injection to the last time of follow-up or the event of interest (progression or death).
Unadjusted PFS distributions will be estimated by the Kaplan and Meier method.
|
From the date of Evomela injection up to 1 year
|
Incidence of treatment related mortality (TRM)
Time Frame: At day 90 post-transplant
|
TRM will be estimated along with 95% posterior credible intervals, assuming beta (.50, .50)
priors.
The probabilities of TRM from the two infusion schedules will also be compared using posterior probabilities of the form Pr(p1 < p2 | data), where pj denotes the probability of the event with schedule j=1,2, based on the data for patients treated at the optimal within-schedule dose chosen by the Bayesian Model Averaging continual reassessment method (BMA-CRM).
|
At day 90 post-transplant
|
Rate of minimal residual disease (MRD)
Time Frame: At day 90 post-transplant
|
MRD negative is defined as absence of phenotypically aberrant clonal plasma cells by nerve growth factor (NGF) on bone marrow aspirates using the EuroFlow standard operation procedure for MRD detection in multiple myeloma (or validated equivalent method) with a minimum sensitivity of 1 in 10^5 nucleated cells or higher.
MRD will be estimated along with 95% posterior credible intervals, assuming beta (.50, .50)
priors.
The probabilities of MRD from the two infusion schedules will also be compared using posterior probabilities of the form Pr(p1 < p2 | data), where pj denotes the probability of the event with schedule j=1,2, based on the data for patients treated at the optimal within-schedule dose chosen by the BMA-CRM.
|
At day 90 post-transplant
|
Complete response rate (CR)
Time Frame: At 90 days post-transplant
|
CR will be estimated along with 95% posterior credible intervals, assuming beta (.50, .50)
priors.
The probabilities of CR from the two infusion schedules will also be compared using posterior probabilities of the form Pr(p1 < p2 | data), where pj denotes the probability of the event with schedule j=1,2, based on the data for patients treated at the optimal within-schedule dose chosen by the BMA-CRM.
|
At 90 days post-transplant
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Qaiser Bashir, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Adjuvants, Immunologic
- Lenograstim
- Melphalan
Other Study ID Numbers
- 2017-0399 (Other Identifier: M D Anderson Cancer Center)
- NCI-2018-00906 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Plasma Cell Myeloma
-
Emory UniversityNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; National Institutes...CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | ISS Stage III Plasma Cell Myeloma | ISS Stage II Plasma Cell Myeloma | ISS Stage I Plasma Cell MyelomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedRefractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma | DS (Durie/Salmon) Stage I Plasma Cell MyelomaUnited States
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)WithdrawnRefractory Plasma Cell Myeloma | DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell MyelomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Plasma Cell LeukemiaUnited States
Clinical Trials on Filgrastim-sndz
-
Franziska WachterHarvard Clinical and Translational Science Center (Harvard Catalyst)RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | MDS | Aml | Myeloid Neoplasm | Myeloid Malignancies | Inherited Bone Marrow Failure SyndromeUnited States
-
Siddhartha GangulyCompleted
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Sarcoma | Uterine Corpus LeiomyosarcomaUnited States
-
Hospital Infantil Universitario Niño Jesús, Madrid...Universitat Autonoma de Barcelona; Instituto de Investigación Sanitaria de... and other collaboratorsCompletedFanconi AnemiaSpain
-
Ayman H QasrawiAstellas Pharma IncWithdrawn
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedNon-Hodgkin's Lymphoma | Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma | MPNST | High-risk SarcomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Multiple Myeloma-Light Chain OnlyUnited States
-
Trio FertilityRecruitingPrimary Ovarian Insufficiency | Premature Ovarian FailureCanada
-
Ottawa Hospital Research InstituteCompletedEarly Stage Breast CancerCanada